Search PubMed⌕ Search

Biomedical subjects

R Ganapati

Publications and source records attributed to R Ganapati.

At least 91 records · Page 5Linked to original sources

Clinical trial with clofazimine in leprosy.

This paper summarises our clinical experience with clofazimine in the treatment of 25 cases of reactive states of lepromatous and borderline leprosy and 7 lepromatous patients not responding to dapsone. Corticosteroids, which had to be given for the control of reactions, could be withdrawn and daspone therapy reintroduced during the period of administration of clofazimine. A schedule for the management of moderately severe reactions is recommended. The results of clofazimine treatment were also equally impressive in the group of patients, possibly harbouring dapsone resistant bacilli (in view of their lack of improvement in spite of administration of dapsone under controlled conditions). Clinical regression was associated with a fall in the mean levels of morphological index from 6.8 to 0.5. The need to realise the real indications of this highly useful drug in the treatment of leprosy is stressed.

Adolescent↗

Bacteremia in leprosy and its relation to distribution of M. leprae in skin.

Evidence of bacillaemia through examination of heparinised blood smears was obtained in 17 of the 20 cases (85%) of untreated leprosy cases belonging to the spectrum ranging from BT to LL. Among 17 cases whose blood smears were positive for AFB, the endothelial cells of blood vessels in skin lesions showed AFB in 11 instances (64.7%) and in 7 (41.2%) of these cases biopsies obtained from apparently normal skin also showed bacilli in the blood vessels. The fact that blood smears may show AFB even in patients belonging to types classifiable as BT-BB in the Ridley Jopling scale (a child aged 3 1/2 years showed this feature) emphasises the importance of investigations to assess thoroughly the extent of bacillation in leprosy patients.

Adolescent↗

Clinical trial of DADDS in lepromatous leprosy.

This presentation reports the results of a short clinical trial with DADDS in 23 patients of lepromatous leprosy. Injections of DADDS administered intramuscularly in a dose of 225 mg every 70 days produced clinical regression noticeable earliest at few week after the secondn injection. A fall in the morphological index from 5.0 to 0.6 was observed in patients who had received from 3 to 7 injections. Erythema nodosum leprosum was encountered in 7 cases, four of which had moderate to severe grades of reaction. It is advisible to discontinue further injection of DADDS if initial signs of ENL are noticed, which are likely to occur after the second injection. These ENL responded well to the usual line of antireaction treatment. DDS level in blood was found to be more than 10 ng/ml before the fresh administration of DADDS upto the seventh injection, representing the period of follow-up in this study.

Adolescent↗

Survey of leprosy in unapproachable and uncovered areas.

Leprosy surveys in tribal population, fishermen and labourers engaged in construction work revealed prevalence rates of 32/10,000, 109/10,000 and 20/10,000 respectively, suggesting that systematic surveys have to be carried out in such population groups, to reach the goal of a "World without leprosy".

Humans↗

The simultaneous inoculation of Mycobacterium leprae and M. intracellulare into nude mice: development of cutaneous leproma and accelleration of foot pad swelling.

Organisms of the non-pathogenic Mycobacterium intracellulare serotype 19 Darden enhanced the pathogenicity of M. leprae when inoculated together into the foot pads of nude mice. This supporting effect could be demonstrated by an accelleration of foot pad swelling, beginning 4 months after inoculation and by the development of cutaneous leproma on dorsal and lateral body sites within 6 months after inoculation. These leproma increased in number and size during the 9 months they were under observation and demonstrated micromorphological characteristics similar to those of human leprosy.

Animals↗